DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA566789
Title:
Evaluation of Immune Responses Mediated by Listeria-Stimulated Human Dendritic Cells: Implications for Cancer Vaccine Therapy
Descriptive Note:
Annual rept. 15 Jun 2011-14 Jun 2012
Corporate Author:
SLOAN-KETTERING INST FOR CANCER RESEARCH NEW YORK
Report Date:
2012-07-01
Pagination or Media Count:
12.0
Abstract:
The purpose of this project is to study the immunomodulatory effect of Listeria on human dendritic cells DCs to optimize Listeria-based DC cancer vaccines. The project aims are 1 Compare the activation and maturation of different human DC subsets in response to Listeria infection. 2 Define the induction of CD4CD8 T-cell and NK cell responses to Listeriaactivated DCs presenting a melanoma tumor-associated antigen. 3 Augment the immunogenicity of Listeria-activated DCs by inhibiting the immunosuppressive enzyme, indoleamine 2,3-dioxygenase. During the initial period of funding, critical parameters and baseline readouts of Listeria infection of monocyte-derived DCs moDCs were identified and validated. Key findings include 1 Listeria infection, including that mediated by attenuated strains, induces moDC maturation and activation. 2 Listeria-treated moDCs are functionally active as potent stimulators of T-cell proliferation. 3 Listeria treatment, as compared with standard inflammatory cytokine stimulation, does not promote the over-expression of inhibitory markers on moDCs. 4 Listeria treatment, as compared with standard inflammatory cytokine stimulation, does not potentiate the expansion of immune-dampening regulatory T-cells by moDCs. These findings confirm the immune-stimulatory properties of Listeria as a vaccine adjuvant. Studies of other DC subtypes are underway to identify the optimal DC for further study in Aims 23.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
